Contrasting Aclarion (ACON) & The Competition

Aclarion (NASDAQ:ACON) is one of 93 publicly-traded companies in the “Medical Services” industry, but how does it weigh in compared to its competitors? We will compare Aclarion to related companies based on the strength of its earnings, valuation, analyst recommendations, risk, institutional ownership, profitability and dividends.

Analyst Recommendations

This is a breakdown of current recommendations for Aclarion and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1	1	0	0	1.50
Aclarion Competitors	625	2493	5122	184	2.58

Aclarion currently has a consensus target price of $11,758.50, indicating a potential upside of 193,774.69%. As a group, “Medical Services” companies have a potential upside of 14.95%. Given Aclarion’s higher probable upside, equities research analysts plainly believe Aclarion is more favorable than its competitors.

Earnings & Valuation

This table compares Aclarion and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Aclarion	$62,948.00	-$6.99 million	0.00
Aclarion Competitors	$9.94 billion	$239.88 million	12.47

Aclarion’s competitors have higher revenue and earnings than Aclarion. Aclarion is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Aclarion has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, Aclarion’s competitors have a beta of 1.53, suggesting that their average stock price is 53% more volatile than the S&P 500.

Insider and Institutional Ownership

7.5% of Aclarion shares are held by institutional investors. Comparatively, 58.1% of shares of all “Medical Services” companies are held by institutional investors. 0.8% of Aclarion shares are held by insiders. Comparatively, 13.3% of shares of all “Medical Services” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Aclarion and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,908.50%	-67.53%	-63.01%
Aclarion Competitors	-901.88%	-59.99%	-13.64%

Summary

Aclarion competitors beat Aclarion on 12 of the 13 factors compared.

Aclarion Company Profile

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.